Medicxi
Life sciences investor building and funding drug-development companies for unmet medical needs
- Venture capital
- London
- Type
- Venture capital
- Based in
- London
- Stages
- Pre-seed, Seed, Series A, Series B+, Growth
- Sector focus
- Biotech & Life Sciences, Hardware & Robotics
- Cheque size
- Above €3M
- Fund size
- Undisclosed
- Founded
- 2016
- Website
- medicxi.com
Medicxi is a European life sciences investment firm founded in 2016 by the former life sciences team of Index Ventures. It has offices in London, Geneva and Jersey.
The team draws on long experience in drug discovery and in developing therapeutics for unmet medical needs, and it both creates and backs biotech companies. The firm is currently investing from its fifth fund, Medicxi V, and also manages the legacy Index Ventures life sciences portfolio. Pharmaceutical and technology groups including GSK, Johnson & Johnson Innovation, Novartis and Verily have invested in its funds. Recent portfolio news includes Vaderis Therapeutics and Ethyreal Bio.
Team
- Giovanni Pericolini, Partner LinkedIn
- Giovanni Mariggi, Partner LinkedIn
- Shyam Masrani, Partner LinkedIn
← All investors · Is this your organisation? Request an update
More investors in the directory
FirstPartyCapital
Specialist investor in AI, data and outcomes-based technology for the marketing and advertising sector
Elbow Beach
Early-stage investor in British clean technologies that cut emissions while improving customer economics
Selvedge Venture
Pre-seed to Series A investor in biotech and data-driven start-ups tackling age-related disease
SFV
Seed to Series B investor in urban, energy and industrial infrastructure technology
Zinal Growth
Growth investor partnering with founders building generational technology companies
Rockley Group
Invests in and advises technology businesses focused on sustainability, energy and resource efficiency
Subscribe to Newsletter
Join me on this exciting journey as we explore the boundless world of web design together.